Biomarin Pharmaceutical's Cost of Goods Sold for the
three
months ended in Sep. 2021 was $104 Mil. Its Revenue for the
three
months ended in Sep. 2021 was $409 Mil.
Biomarin Pharmaceutical's COGS to Revenue for the
three
months ended in Sep. 2021 was 0.25.
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Biomarin Pharmaceutical's Gross Margin % for the
three
months ended in Sep. 2021 was 74.67%.
Biomarin Pharmaceutical COGS-to-Revenue Historical Data
The historical data trend for Biomarin Pharmaceutical's COGS-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.
Biomarin Pharmaceutical COGS-to-Revenue Related Terms
Thank you for viewing the detailed overview of Biomarin Pharmaceutical's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin's Roctavian (hemophilia A gene therapy) and vosoritide (treatment for achondroplasia) are poised to potentially launch in the 2021-22 timeframe.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
0.18(0.21%) Volume: 1,146,770 4:00PM EST
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:BMRN has been successfully added to your 
